Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-P01 in advanced pancreatic cancer
NCT03645148Phase 1Completed
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Oct 2017
- Primary completion
- Nov 2020
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of iNeo-Vac-P01 in pancreatic cancer (PC), sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: Objective Response Rate at 2 years and Adverse Events at 1 year. Started Oct 2017; status: completed.
02
Drugs
iNeo-Vac-P01
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03645148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645148.